@ippsecretariat.org📢 Three stories, one newsletter!
It's been a busy few weeks for the #100DaysMission. We've put three updates we wanted you to hear all in one place.
Read more (plus how to get involved) in the newsletter 👇
mailchi.mp/ippsecretar...
@bioprevail.bsky.socialDr Lisa McDonald, Global Health Security Fund, on the problem behind the BioPREVAIL Ă— @cepi.net Biosecurity Innovation Challenge.
đź”— Startups, labs, companies and research groups can apply by 31 October: bioprevail.org/apply
#Biosecurity #Opportunity #Startup #PandemicPreparedness #100DaysMission
@artificialscience.bsky.socialWorld leaders meet at the UN this week to lock in pandemic pledges. The real news: an AI 'factory' quietly built to design vaccines in days, not months. Here's what it can (and can't) do yet. #PandemicPreparedness #AI #GlobalHealth #100DaysMission
@ippsecretariat.orgThank you for following along with today's event as part of @devex.com Impact House @ #UNGA81, and thank you to our host Rumbie Chakamba.
You can sign up to receive a recording of the event via Devex here: dvx.cm/bgxtab
@ippsecretariat.orgClosing the event, Dr Victor Dzau highlighted some final considerations:
1/ Monitoring and evaluation is crucial: we have the #100DaysMission Scorecard, which will continue until at least 2028 led by @impactglobalhealth.bsky.social following IPPS' sunset in early 2027.
@ippsecretariat.orgMalcolm Sowah: ''It's important that we maintain capabilities between crises. This means effective surveillance, clinical trial networks and regulatory readiness.''
@ippsecretariat.org''Industry want to be a part of the solution. Contracts need to be compatible with business requirements - legal and commercial obligations - happening right now with BDBV.'' - James Anderson, IFPMA
@ippsecretariat.org''Brazil's COVID response was based on existing institutions which requires sustained investment. A new biotech industry incl. fill & finish for vaccines - responds to Brazil's needs & can be used regionally, capacity allowing.'' - Priscila Ferraz Soares
@ippsecretariat.orgIFPMA's James Anderson on industry perspectives: ''Pandemic preparedness is insurance for the world. We all need it. Industry have supported the #100DaysMission since the beginning - expertise, products, science - to help the world prepare and respond to outbreaks''
@ippsecretariat.orgSowah continues: ''We also launched a Biological Security Strategy which complements the PPR strategy. We also have a cross-govt Board on 100DM. The 100 day goal can’t sit separately from national efforts on surveillance and manufacturing efforts”
@ippsecretariat.orgMalcolm Sowah of the UK Mission to the UN on UK progress: ''UK just launched PPR strategy which is the centre of this ambition to take rapid & coordinated action. It draws on COVID-19 and simulation exercise on PPR. Moving from preparing from one disease to many.''
@ippsecretariat.orgDr Priscila Ferraz Soares @fiocruz.bsky.social highlights: ''Brazil has launched new industrial policy focused on reducing external dependence, increasing mass production & new legislation on the health complex as a national asset for health security & innovation.''
@ippsecretariat.orgOur second panel session is on ''Delivering the 100 Days Mission: Preparedness in Practice''
Perspectives on embedding the 100 day goal in the strategies, policies & capabilities to enable rapid response w/ inputs from Fiocruz, IFPMA and the UK Mission to the UN.
@ippsecretariat.org@ippsecretariat.org@medicinespatentpool.org's Charles Gore comments: ''We need to have licenses in place and then triggered before a pandemic. Trying to put things in place interpandemic times to move as quickly as possible''
@ippsecretariat.orgOn BDBV, Sheila Mburu reflects on diagnostics availability: ''At Day 100 we still don’t have a true point-of-care test. This is essential for communities that don’t have access to centralised testing.''
@ippsecretariat.org@cepi.net's Dr Richard Hatchett on progress: ''The #100DaysMission is an aspiration, but BDBV is a perfect case to tell us how we’ve progressed towards it. We’re almost at Phase 1 trials. This is an example of Disease X in practice. 100DM is a multi year investment to get there.''
@ippsecretariat.org@ippsecretariat.org's Sheila Mburu (contd): ''Regulatory harmonisation in an emergency context is also key. At IPPS, we are working with @path.org to landscape the harmonisation approach across regulatory issues.''
@ippsecretariat.org@ippsecretariat.org's Sheila Mburu reflects on the ongoing BDBV outbreak: ''In this ongoing outbreak, we are flying blind, need to detect early in order to respond...having sample access and finalising the PABS annex is key to this''
@ippsecretariat.org@dndi.org's Rachel Cohen highlights a key gap: ''As set out by WHO & Africa CDC in The Lancet, although we have the beginnings of an ecosystem for vaccines, we have no ecosystem for therapeutics or for diagnostics''